Chandrani Chattopadhyay, B.S., M.S., Ph.D.
Department of Melanoma Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Instructor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2007 | UT MD Anderson Cancer Center, Houston, TX, USA, Pre-Doctoral & Post Doctoral Fellow, Molecular genetics and Head & Neck Cancer |
| 2002 | Bose Institute/Calcutta University, Calcutta, IND, PHD, Biochemistry |
| 1994 | Calcutta University, Calcutta, IND, MS, Biochemistry |
| 1992 | Bethune College, Calcutta, IND, BS, Chemistry |
Postgraduate Training
| 2002-2007 | Postdoctoral Fellow, Molecular Genetics and Head & Neck Surgery Research, MD Anderson Cancer Center, Houston, TX |
| 2000-2002 | Predoctoral Fellow, Molecular Genetics, MD Anderson Cancer Center, Houston, TX |
| 1997-2000 | Senior Research Fellow, Bose Institute, Calcutta |
| 1995-1997 | Research Fellowship, Bose Institute, Calcutta |
Experience & Service
Other Professional Positions
Research Scientist, MD Anderson Cancer Center, Houston, TX, 2007 - 2011
Honors & Awards
| 2013 | The Eye Cancer Foundation Fellowship, The Liverpool Ocular Oncology Research Group's |
| 1994 | Shanti Bhakta Memorial Award |
| 1994 - 2000 | Fellow of Council of Scientific & Industrial Research |
Grant & Contract Support
| Date: | 2024 - 2024 |
| Title: | Determine the mechanisms of resistance to metabolic inhibition of metastatic uveal melanoma in the liver |
| Funding Source: | MDACC IRG |
| Role: | Principal Investigator |
| Date: | 2022 - 2025 |
| Title: | Tumor and microenvironment inflammatory pathways as targets for improvement of melanoma patient outcomes |
| Funding Source: | Dr. Miriam and Sheldon G Adelson Research Foundation |
| Role: | Co-Investigator |
| ID: | FP17003 |
| Date: | 2021 - 2022 |
| Title: | Targeting metabolic vulnerabilities in uveal melanoma using a novel orthotopic mouse model for liver metastasis |
| Funding Source: | NIH NCATS Center for Clinical and Translational Sciences Preclinical Modeling Pilot Program |
| Role: | Co-Principal Investigator |
| ID: | N/A |
| Date: | 2021 - 2022 |
| Title: | Targeting succinate dehydrogenase a in metastatic uveal melanoma: effect on growth and metabolic profile |
| Funding Source: | Developmental Research Program (DRP) |
| Role: | Principal Investigator |
| ID: | Melanoma SPORE DRP |
| Date: | 2021 - 2024 |
| Title: | The M D Anderson uveal melanoma program |
| Funding Source: | M D Anderson Cancer Center |
| Role: | Co-Investigator |
| ID: | MRP |
| Date: | 2019 - 2022 |
| Title: | Tumor and microenvironment oxidant pathways as targets for improvement of melanoma patient outcomes |
| Funding Source: | Dr. Miriam and Sheldon G. Adelson. Medical Research Foundation |
| Role: | Co-Investigator |
| ID: | 8AMFR 2019-2020 |
| Date: | 2019 - 2020 |
| Title: | Exploiting metabolic vulnerabilities of metastatic uveal melanoma for therapeutic intervention |
| Funding Source: | UTMDACC Melanoma SPORE Developmental Research Project |
| Role: | Principal Investigator |
| ID: | 1 P50CA221703-01A1 |
| Date: | 2017 - 2019 |
| Title: | Aberrant ROS and RNS pathways: likely prognostic and predictive markers, and targets for overcoming resistance to therapy |
| Funding Source: | Dr. Miriam and Sheldon G. Adelson Medical Research Foundation |
| Role: | Co-Investigator |
| Title: | Targeting vulnerabilities in mitochondrial energy metabolism in metastatic uveal melanoma: effect on tumor growth and metabolic profile |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | N/A |
Selected Publications
Peer-Reviewed Articles
- Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, Ali MM, Khan FS, Prabhu VV, Lorenzi P, Burton E, Morey RR, Lazcano R, Davies MA, Patel SP, Grimm EA. Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. bioRxiv, 2024. e-Pub 2024. PMID: 38293232.
- Chattopadhyay C, Bhattacharya R, Roszik J, Khan FS, Wells GA, Villanueva H, Qin Y, Bhattacharya R, Patel SP, Grimm EA. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers (Basel) 14(24), 2022. e-Pub 2022. PMID: 36551732.
- Mattei J, Ballhausen A, Bassett R, Shephard M, Chattopadhyay C, Hudgens C, Tetzlaff M, Woodman S, Sato T, Patel SP. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. Melanoma Res 30(6):574-579, 2020. e-Pub 2020. PMID: 32976223.
- Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci 60(13):4187-4195, 2019. PMID: 31596927.
- Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res 28(3):357-9, 2015. e-Pub 2015. PMID: 25515650.
- Jayakumar A, Chattopadhyay C, Wu HK, Briggs K, Henderson Y, Kang Y, Ramdas L, Sharma S, Radjendirane V, Shellenberger TD, Clayman GL. LEKTI, A Physiological Inhibitor of Multiple Serine Proteinases, Blocks Migration and Invasion of Head and Neck Squamous Cell Carcinoma (HNSCC) Cells. MOJ Proteomics Bioinform 1(3), 2014. e-Pub 2014.
- Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One 9(2):e83957, 2014. e-Pub 2014. PMID: 24551032.
- Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting. Int J Cancer 131(2):E56-65, 2012. e-Pub 2012. PMID: 22020736.
- Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EA. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer 63(6):940-9, 2011. e-Pub 2011. PMID: 21745040.
- Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck 30(8):991-1000, 2008. PMID: 18327775.
- Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, Wang M, Briggs K, Clayman GL. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg 134(2):190-7, 2008. PMID: 18283163.
- Shellenberger TD, Mazumdar A, Henderson Y, Briggs K, Wang M, Chattopadhyay C, Jayakumar A, Frederick M, Clayman GL. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res 65(24):11501-9, 2005. PMID: 16357159.
- Chattopadhyay C, Hawke D, Kobayashi R, Maity SN. Human p32, interacts with B subunit of the CCAAT-binding factor, CBF/NF-Y, and inhibits CBF-mediated transcription activation in vitro. Nucleic Acids Res 32(12):3632-41, 2004. e-Pub 2004. PMID: 15243141.
- Chattopadhyay C, Sau S, Mandal NC. Cloning and characterization of the promoters of temperate mycobacteriophage L1. J Biochem Mol Biol 36(6):586-92, 2003. PMID: 14659078.
Patient Reviews
CV information above last modified August 21, 2024